Basal Insulin Inadequacy versus Failure – Using Appropriate Terminology
Open Access
- 1 January 2015
- journal article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 11 (2), 79-80
- https://doi.org/10.17925/EE.2015.11.02.79
Abstract
This editorial focuses on appropriate terminology related to basal insulin therapy. The authors analyse current usage of ‘basal insulin failure’, and propose ‘basal insulin inadequacy’ as a better descriptor for persons not responding to basal insulin alone. The pharmacokinetic and pharmacodynamic differences between various basal insulin preparations are highlighted. Based upon these, a drug-specific definition for insulin inadequacy is suggested, instead of a generic class-based labelling.Keywords
This publication has 12 references indexed in Scilit:
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 2014
- Switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetesDiabetes & Metabolism, 2014
- Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UKJournal of Medical Economics, 2014
- Cost‐effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin – from the UK health care cost perspectiveDiabetes, Obesity and Metabolism, 2014
- Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal InsulinDiabetes Therapy, 2013
- Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 DiabetesDiabetes Care, 2012
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trialsDiabetes, Obesity and Metabolism, 2012
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetesDiabetes, Obesity and Metabolism, 2012
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 DiabetesAnnals of Internal Medicine, 2011
- Degludec insulin: A novel basal insulinIndian Journal of Endocrinology and Metabolism, 2011